tiprankstipranks
Marker Therapeutics Inc (MRKR)
NASDAQ:MRKR

Marker Therapeutics (MRKR) Income Statement

484 Followers

Marker Therapeutics Income Statement

Last quarter (Q1 2024), Marker Therapeutics's total revenue was $1.24M, a decrease of -62.41% from the same quarter last year. In Q1, Marker Therapeutics's net income was $-2.39M. See Marker Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 3.06M$ 3.31M$ 9.01M$ 1.24M$ 466.79K$ 213.19K
Cost of Revenue
------
Gross Profit
$ 3.06M$ 3.31M----
Operating Expense
$ 22.47M$ 17.89M$ -38.96M$ -40.72M$ 29.35M$ 22.74M
Operating Income
$ -19.41M$ -14.58M$ -38.96M$ -40.72M$ -28.89M$ -22.53M
Net Non Operating Interest Income Expense
$ 477.27K$ 539.16K$ 248.06K$ 5.70K$ 148.74K$ 1.08M
Other Income Expense
$ -4.73M-$ -9.01M$ -1.24M$ 31.00K$ 18.00K
Pretax Income
$ -14.20M$ -14.04M$ -29.70M$ -39.47M$ -28.71M$ -21.43M
Tax Provision
$ 3.67K$ 3.67K$ -1.02M$ -103.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -1.03M$ -8.24M$ -29.93M$ -41.88M$ -28.71M$ -21.43M
Basic EPS
$ -1.17$ -1.87$ -3.58$ -5.47$ -0.61$ -0.47
Diluted EPS
$ -1.16$ -1.87$ -3.58$ -5.47$ -0.61$ -0.47
Basic Average Shares
$ 35.31M$ 8.81M$ 8.35M$ 7.65M$ 47.04M$ 45.59M
Diluted Average Shares
$ 35.16M$ 8.81M$ 8.35M$ 7.65M$ 47.04M$ 45.59M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 22.47M$ 17.89M$ -38.96M$ -40.72M$ 29.35M$ 22.74M
Net Income From Continuing And Discontinued Operation
$ -7.65M$ -8.24M$ -29.93M$ -41.88M$ -28.71M$ -21.43M
Normalized Income
$ -6.87M$ -11.09M--$ -28.74M$ -21.45M
Interest Expense
------
EBIT
$ -14.40M$ -14.58M$ -29.70M$ -39.47M$ -28.89M$ -22.53M
EBITDA
$ -14.40M$ -14.58M$ -26.02M$ -36.31M$ -27.81M$ -22.24M
Currency in USD

Marker Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis